MiNK Therapeutics Inc
XNAS:INKT
| Market Cap (Intraday) | 60.58M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $11.68 |
| 50-Day MA | $11.19 |
| 200-Day MA | $11.38 |
MiNK Therapeutics Inc Stock, XNAS:INKT
149 5th Avenue, Suite 500, New York, New York 10010
United States of America
Phone: +1.212.994.8250
Number of Employees: 23
Description
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.